Introduction
Recently, a signifi cant association was identifi ed between a rare rs75932628-T variant encoding R47H in the TREM2 gene and an increased risk for Alzheimer's disease (AD) [1, 2] . TREM2 forms a signaling complex with DAP12 expressed on monocytes/macrophages, dendritic cells, osteoclasts, and microglia. Loss-of-function muta tions in either DAP12 or TREM2 are identifi ed in patients with Nasu-Hakola disease, a rare autosomal recessive disorder characterized by presenile dementia and multifocal bone cysts. TREM2 binds to bacterial components and Hsp60, although endogenous ligands remain unknown. R47H located within the extracellular immunoglobulin-like domain of TREM2 possibly causes a reduced affi nity of TREM2 for putative ligands. Knockdown of TREM2 on mouse microglia inhibits phagocytosis of apoptotic neurons and stimulates production of tumor necrosis factor-alpha (TNFα) and interleukin-1-beta (IL-1β), suggesting a pivotal role for TREM2 in the clearance of damaged neural tissues to resolve damageinduced infl ammation. TREM2 is upregulated in amyloid plaque-associated microglia in mouse models of AD, suggesting an active role for TREM2 in the clearance of deposited amyloid-β by microglia. However, the precise pathological role of TREM2-expressing microglia in AD brains remains unknown.
Findings
By immunohistochemistry (IHC), we studied the expression of TREM2 in serial sections of formalin-fi xed paraffi n-embedded tissues of the frontal cortex and the hippocampus derived from fi ve patients with AD, four patients with amyotrophic lateral sclerosis, and four neurologically normal control subjects. Written informed consent was obtained from all of the cases. Th e ethics committee of the corresponding institutions approved the present study. Th e tissue sections were treated for antigen retrieval in 10 mM citrate sodium buff er, pH 6.0, at 110°C for 15 minutes in a temperature-controlled pressure chamber (Biocare Medical, Concord, CA, USA). First, we evaluated the specifi city of commercially available anti-TREM2 antibodies, such as HPA010917 (Sigma-Aldrich, St. Louis, MO, USA), AF1828 (R&D Systems, Inc., Minneapolis, MN, USA), 2B5 (Novus Biologicals, Inc., Littleton, CO, USA), bs-2723R (Bioss, Woburn, MA, USA), PA5-18763 (Th ermo Fisher Scientifi c Inc., Waltham, MA, USA), ab69405 (Abcam, Cambridge, UK), and ab85851 (Abcam) by Western blot of recombinant human TREM2 protein expressed in HEK293 cells. Only HPA010917, AF1828, and 2B5, but not others, reacted with TREM2 on the blot ( Figure 1 ). Next, we studied TREM2 expression in spleen, bone marrow, and the brain by IHC with HPA010917, AF1828, and 2B5. Only HPA010917 labeled monocytes/macro phages, dendritic cells, and osteoclasts (Figure 2a,b) . Th us, only HPA010917 satisfi ed the specifi city and the reactivity to TREM2 both in vitro and in vivo. By IHC with HPA010917, we found an accu mulation of Iba1-and DA12-immunoreactive microglia, but Iba1-, HLA-DR-, CD68-, or DAP12-immunoreactive microglia did not express TREM2 in any of the cases examined (Figures 2c,d and 3a-f ). In contrast, TREM2 was identifi ed in small subpopulations of intravascular monocytes/macro phages and neurons and was totally absorbed by preincubation with recombinant protein (Figures 2c-f and 3b) .
Here we found that Iba1-immunoreactive microglia do not express TREM2 in AD and control brains. Previous studies by IHC with uncharacterized antibodies showed that microglia express TREM2 in the mouse and human cerebral cortex, where it is located in the Golgi complex [3] . Although the possibility exists that neuronal staining of TREM2 refl ects immunoreactivity of cross-reactive pro teins, the validation requires the development of additional antibodies highly specifi c for distinct epitopes of TREM2. Not all microglia in the mouse brain express TREM2, and its levels are reduced in cultured microglia 
